🦠 “I was resistant to nine antibiotics,” says AMR survivor, Vanessa Carter. “I had to learn how to walk again. It took me years to recover.”. The human impact of antimicrobial resistance is real – but it is preventable. 🔗 Read our article to find out how we’re fighting back:

The global population is ageing, and with it, the burden of infectious disease is set to grow. Innovative health policies are needed to help strengthen economies, bolster health services, and ensure people are able to live healthy lives. 🔗Read more:

It’s a time of life when many may feel invincible, but adolescents are at risk of invasive meningococcal disease (IMD), a bacterial infection that can be life-threatening. Read our article to hear from IMD survivor Kate – and mother Michelle, who lost her son Ryan within 24

#News for #Investors and #Media: Today we announced that one of our investigational oral anti-infectives has been accepted for priority review by US FDA. Learn more:

Hi again, we’re following up to apologise for the inaccurate response you previously received. To clarify, this product is made by GSK in India. Please can you contact our GSK India team so we can assist you further – you can find their details here:

Take a look at the highlights from our strong Q2 2025 performance 👇 . More information for media and investors: $GSK.

#Investors: Join our CEO Emma Walmsley and other members of our leadership team for our Q2 2025 results webcast at 12:00 BST, 07:00 EDT. $GSK

#Investors and #Media: Cautionary statement regarding forward-looking statements & the definitions & reconciliations for non-IFRS measures for our results. CER% represents constant exchange rates. £% or AER% represents actual exchange rates.

Our CEO Emma Walmsley announces another quarter of excellent performance. Strong results in Q2 2025 were driven by double-digit growth in Specialty Medicines. More information for media and investors: $GSK #Q2Results

We’re announcing our Q2 2025 results tomorrow at 0700 BST, 0200 EDT. $GSK

#News for #Investors and #Media: . Today we are sharing new findings on Dementia and Alzheimer’s Disease at #AAIC2025, building on our leadership in immunology and inflammation. 🔗 Find out more:

It’s #WorldHepatitisDay and we are proud to sponsor @Hep_Alliance in raising awareness of chronic hepatitis B (CHB).

#News for #investors and #media: We’ve announced a collaboration with Hengrui Pharma to develop up to 12 innovative medicines across respiratory, immunology and oncology. Find out more:

#News for #Investors and #Media . The European Commission has granted marketing authorisation for one of our blood cancer therapies. For more information, visit:

#News for #Investors and #Media: The US FDA has approved a new presentation of one of our vaccines. Learn more:

🚀 At GSK, R&D is central to our purpose: to get ahead of disease together. Much of our cutting-edge innovation happens in the UK, where we invested £1.5bn in 2024 alone. That’s why we welcome the UK Government’s new Life Sciences Sector Plan. 🔗 Read the plan here:

Many blood cancer patients face lifelong treatment challenges, but thankfully scientists are working hard to give them the quality of life they deserve. 🔗 Find out why patients living with incurable blood cancers need more treatment options in our latest Behind the Science

#News for #Investors and #Media: Data presented at #IAS2025 by @ViiVHC (our specialist HIV company) reinforce the importance of providing people living with #HIV with innovative treatment options that best suit their individual needs and preferences. 🔗 Find out more:

#News for #Investors and #Media: @ViiVHC (our specialist HIV company) has expanded its voluntary license with the Medicines Patent Pool to include further innovative treatments alongside prevention to enable increased access and reach those most impacted by #HIV. 🔗 Find out